REVOLUTIONIZING the TREATMENT of VIRAL EPIDEMICS
A RADICAL, INNOVATIVE WAY TO TREAT RESPIRATORY VIRUS
CytoAgents is a privately held biotechnology company focused on the development of innovative pharmaceutical products for the treatment of influenza and other viral infectious diseases including Covid-19. We are taking a radically different approach to solve this health problem.
Using immunotherapy, we are targeting the underlying cause of life-threatening symptoms associated with influenza and cytokine release syndrome by managing the natural immune response to the disease. Currently, there are no viable treatment options for the majority of these patients.
GP1681 will treat cytokine release syndrome symptoms by modulating the immune system (unlike anti-viral medications) throughout the course of influenza. GP1681 decreases the cytokine levels and therefore reduces mortality.
GP1681 has an FDA accepted Investigational New Drug (IND) application and is ready to start Phase I human clinical trials.
AN EPIDEMIC: A DEVASTATING PUBLIC HEALTH THREAT
COVID-19 AND INFLUENZA
New strains and combinations of influenza strains circulate every year and the Covid-19 pandemic is shining a spotlight on our current inadequate pharmacological responses.
The cornerstone of influenza therapy is vaccination and anti-viral medications, both of which have significant limitations. Currently, there are no effective treatments to treat these respiratory symptoms associated with an average of 13M medical visits annually.
GP1681: ADDRESSING AN UNMET NEED
CytoAgents’ lead candidate, GP1681, addresses a clear unmet need and will expand the category for therapy options available for the treatment of influenza. GP1681 may address other conditions associated with cytokine release syndrome including Covid-19.